Edgar Filing: VOLITIONRX LTD - Form 8-K

VOLITIONRX LTD Form 8-K May 20, 2013

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

# PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2013 (May 15, 2013)

#### **VolitionRX Limited**

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of Incorporation)

**000-30402** (Commission File Number)

91-1949078 (IRS Employer Identification Number)

1 Scotts Road

#24-05 Shaw Centre

Singapore 228208

(Address of principal executive offices)

(201) 618-1750

(Registrant s Telephone Number)

### Edgar Filing: VOLITIONRX LTD - Form 8-K

. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  . Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  . Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		propriate box below under any of the fol	if the Form 8-K filin lowing provisions:	g is intended to s	imultaneously sati	isfy the filing oblig	ation of
. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	. Writter	n communications p	ursuant to Rule 425 u	under the Securit	ies Act (17 CFR 2	30.425)	
240.14d-2(b))	. Soliciti	ng material pursuar	nt to Rule 14a-12 und	er the Exchange	Act (17 CFR 240.	14a-12)	
. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			unications pursuant t	o Rule 14d-2(b)	under the Exchanş	ge Act (17 CFR	
	. Pre-cor	mmencement comm	unications pursuant t	to Rule 13e-4(c)	under the Exchang	ge Act (17 CFR 240	).13e-4(c))

Edgar Filing: VOLITIONRX LTD - Form 8-K

#### **VOLITIONRX LIMITED**

#### Form 8-K

### **Current Report**

ITEM 5.02.

## DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

Effective May 15, 2013, Satu Vainikka ( Dr. Vainikka ) resigned from all positions with the Company including, but not limited to, that of Director. Dr. Vainikka s resignation did not involve any disagreement with the Company on any matter relating to the Company s operations, policies, practices, or otherwise.

On May 16, 2013, the Company s Board of Directors accepted Dr. Vainikka s resignation.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **VOLITIONRX LIMITED**

Date: May 20, 2013 By: /s/ Cameron Reynolds

Cameron Reynolds

Chief Executive Officer & President